No major association between TGFBR1*6A and prostate cancer

Virginia Kaklamani, Lisa Baddi, Diana Rosman, Junjian Liu, Nathan Ellis, Carole Oddoux, Harry Ostrer, Yu Chen, Habibul Ahsan, Kenneth Offit, Boris Pasche

Research output: Contribution to journalArticle

Abstract

Prostate cancer is the most commonly diagnosed cancer in men and one of the leading causes of cancer deaths. There is strong genetic evidence indicating that a large proportion of prostate cancers are caused by heritable factors but the search for prostate cancer susceptibility genes has thus far remained elusive. TGFBR1*6A, a common hypomorphic variant of the type I Transforming Growth Factor Beta receptor, is emerging as a tumor susceptibility allele that predisposes to the development of breast, colon and ovarian cancer. The association with prostate cancer has not yet been explored. A total of 907 cases and controls from New York City were genotyped to test the hypothesis that TGFBR1*6A may contribute to the development of prostate cancer. TGFBR1*6A allelic frequency among cases (0.086) was slightly higher than among controls (0.080) but the differences in TGFBR1*6A genotype distribution between cases and controls did not reach statistical significance (p = 0.67). Our data suggest that TGFBR1*6A does not contribute to the development of prostate cancer.

Original languageEnglish (US)
JournalBMC Genetics
Volume5
DOIs
StatePublished - Sep 22 2004

Fingerprint

Prostatic Neoplasms
Neoplasms
Neoplasm Genes
Ovarian Neoplasms
Colonic Neoplasms
Cause of Death
Alleles
Genotype
Breast Neoplasms

ASJC Scopus subject areas

  • Genetics
  • Genetics(clinical)

Cite this

Kaklamani, V., Baddi, L., Rosman, D., Liu, J., Ellis, N., Oddoux, C., ... Pasche, B. (2004). No major association between TGFBR1*6A and prostate cancer. BMC Genetics, 5. https://doi.org/10.1186/1471-2156-5-28

No major association between TGFBR1*6A and prostate cancer. / Kaklamani, Virginia; Baddi, Lisa; Rosman, Diana; Liu, Junjian; Ellis, Nathan; Oddoux, Carole; Ostrer, Harry; Chen, Yu; Ahsan, Habibul; Offit, Kenneth; Pasche, Boris.

In: BMC Genetics, Vol. 5, 22.09.2004.

Research output: Contribution to journalArticle

Kaklamani, V, Baddi, L, Rosman, D, Liu, J, Ellis, N, Oddoux, C, Ostrer, H, Chen, Y, Ahsan, H, Offit, K & Pasche, B 2004, 'No major association between TGFBR1*6A and prostate cancer', BMC Genetics, vol. 5. https://doi.org/10.1186/1471-2156-5-28
Kaklamani V, Baddi L, Rosman D, Liu J, Ellis N, Oddoux C et al. No major association between TGFBR1*6A and prostate cancer. BMC Genetics. 2004 Sep 22;5. https://doi.org/10.1186/1471-2156-5-28
Kaklamani, Virginia ; Baddi, Lisa ; Rosman, Diana ; Liu, Junjian ; Ellis, Nathan ; Oddoux, Carole ; Ostrer, Harry ; Chen, Yu ; Ahsan, Habibul ; Offit, Kenneth ; Pasche, Boris. / No major association between TGFBR1*6A and prostate cancer. In: BMC Genetics. 2004 ; Vol. 5.
@article{09137eb510bb49e9ae46a1c7ac632171,
title = "No major association between TGFBR1*6A and prostate cancer",
abstract = "Prostate cancer is the most commonly diagnosed cancer in men and one of the leading causes of cancer deaths. There is strong genetic evidence indicating that a large proportion of prostate cancers are caused by heritable factors but the search for prostate cancer susceptibility genes has thus far remained elusive. TGFBR1*6A, a common hypomorphic variant of the type I Transforming Growth Factor Beta receptor, is emerging as a tumor susceptibility allele that predisposes to the development of breast, colon and ovarian cancer. The association with prostate cancer has not yet been explored. A total of 907 cases and controls from New York City were genotyped to test the hypothesis that TGFBR1*6A may contribute to the development of prostate cancer. TGFBR1*6A allelic frequency among cases (0.086) was slightly higher than among controls (0.080) but the differences in TGFBR1*6A genotype distribution between cases and controls did not reach statistical significance (p = 0.67). Our data suggest that TGFBR1*6A does not contribute to the development of prostate cancer.",
author = "Virginia Kaklamani and Lisa Baddi and Diana Rosman and Junjian Liu and Nathan Ellis and Carole Oddoux and Harry Ostrer and Yu Chen and Habibul Ahsan and Kenneth Offit and Boris Pasche",
year = "2004",
month = "9",
day = "22",
doi = "10.1186/1471-2156-5-28",
language = "English (US)",
volume = "5",
journal = "BMC Genetics",
issn = "1471-2156",
publisher = "BioMed Central",

}

TY - JOUR

T1 - No major association between TGFBR1*6A and prostate cancer

AU - Kaklamani, Virginia

AU - Baddi, Lisa

AU - Rosman, Diana

AU - Liu, Junjian

AU - Ellis, Nathan

AU - Oddoux, Carole

AU - Ostrer, Harry

AU - Chen, Yu

AU - Ahsan, Habibul

AU - Offit, Kenneth

AU - Pasche, Boris

PY - 2004/9/22

Y1 - 2004/9/22

N2 - Prostate cancer is the most commonly diagnosed cancer in men and one of the leading causes of cancer deaths. There is strong genetic evidence indicating that a large proportion of prostate cancers are caused by heritable factors but the search for prostate cancer susceptibility genes has thus far remained elusive. TGFBR1*6A, a common hypomorphic variant of the type I Transforming Growth Factor Beta receptor, is emerging as a tumor susceptibility allele that predisposes to the development of breast, colon and ovarian cancer. The association with prostate cancer has not yet been explored. A total of 907 cases and controls from New York City were genotyped to test the hypothesis that TGFBR1*6A may contribute to the development of prostate cancer. TGFBR1*6A allelic frequency among cases (0.086) was slightly higher than among controls (0.080) but the differences in TGFBR1*6A genotype distribution between cases and controls did not reach statistical significance (p = 0.67). Our data suggest that TGFBR1*6A does not contribute to the development of prostate cancer.

AB - Prostate cancer is the most commonly diagnosed cancer in men and one of the leading causes of cancer deaths. There is strong genetic evidence indicating that a large proportion of prostate cancers are caused by heritable factors but the search for prostate cancer susceptibility genes has thus far remained elusive. TGFBR1*6A, a common hypomorphic variant of the type I Transforming Growth Factor Beta receptor, is emerging as a tumor susceptibility allele that predisposes to the development of breast, colon and ovarian cancer. The association with prostate cancer has not yet been explored. A total of 907 cases and controls from New York City were genotyped to test the hypothesis that TGFBR1*6A may contribute to the development of prostate cancer. TGFBR1*6A allelic frequency among cases (0.086) was slightly higher than among controls (0.080) but the differences in TGFBR1*6A genotype distribution between cases and controls did not reach statistical significance (p = 0.67). Our data suggest that TGFBR1*6A does not contribute to the development of prostate cancer.

UR - http://www.scopus.com/inward/record.url?scp=25444506226&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=25444506226&partnerID=8YFLogxK

U2 - 10.1186/1471-2156-5-28

DO - 10.1186/1471-2156-5-28

M3 - Article

C2 - 15385056

AN - SCOPUS:25444506226

VL - 5

JO - BMC Genetics

JF - BMC Genetics

SN - 1471-2156

ER -